Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Noninvasive fetal RhD status determination in early pregnancy.

Manzanares S, Entrala C, Sánchez-Gila M, Fernández-Rosado F, Cobo D, Martinez E, Molina L, Reche R, Pineda A, Gallo JL.

Fetal Diagn Ther. 2014;35(1):7-12. doi: 10.1159/000356078. Epub 2013 Dec 6.

PMID:
24335165
2.

Diagnostic accuracy of fetal rhesus D genotyping using cell-free fetal DNA during the first trimester of pregnancy.

Vivanti A, Benachi A, Huchet FX, Ville Y, Cohen H, Costa JM.

Am J Obstet Gynecol. 2016 Nov;215(5):606.e1-606.e5. doi: 10.1016/j.ajog.2016.06.054. Epub 2016 Jul 5.

PMID:
27393271
3.

Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium.

Minon JM, Gerard C, Senterre JM, Schaaps JP, Foidart JM.

Transfusion. 2008 Feb;48(2):373-81. Epub 2007 Nov 26.

4.

Non-invasive fetal RHD genotyping in the first trimester of pregnancy.

Cardo L, García BP, Alvarez FV.

Clin Chem Lab Med. 2010 Aug;48(8):1121-6. doi: 10.1515/CCLM.2010.234.

PMID:
20482298
5.

Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy.

Wikman AT, Tiblad E, Karlsson A, Olsson ML, Westgren M, Reilly M.

Obstet Gynecol. 2012 Aug;120(2 Pt 1):227-34. doi: 10.1097/AOG.0b013e31825d33d9.

PMID:
22776962
6.

Non-invasive fetal RHD exon 7 and exon 10 genotyping using real-time PCR testing of fetal DNA in maternal plasma.

Hromadnikova I, Vechetova L, Vesela K, Benesova B, Doucha J, Kulovany E, Vlk R.

Fetal Diagn Ther. 2005 Jul-Aug;20(4):275-80.

PMID:
15980640
7.

The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible.

Müller SP, Bartels I, Stein W, Emons G, Gutensohn K, Köhler M, Legler TJ.

Transfusion. 2008 Nov;48(11):2292-301. doi: 10.1111/j.1537-2995.2008.01843.x. Epub 2008 Aug 7.

PMID:
18694461
8.

Standardization non-invasive fetal RHD and SRY determination into clinical routine using a new multiplex RT-PCR assay for fetal cell-free DNA in pregnant women plasma: results in clinical benefits and cost saving.

Macher HC, Noguerol P, Medrano-Campillo P, Garrido-Márquez MR, Rubio-Calvo A, Carmona-González M, Martin-Sánchez J, Pérez-Simón JA, Guerrero JM.

Clin Chim Acta. 2012 Feb 18;413(3-4):490-4. doi: 10.1016/j.cca.2011.11.004. Epub 2011 Nov 27.

PMID:
22133782
9.

Clinical application of midtrimester non-invasive fetal RHD genotyping and identification of RHD variants in a mixed-ethnic population.

Grande M, Ordoñez E, Cirigliano V, Cid J, Grau E, Pericot A, Teixido I, Marin JL, Borrell A.

Prenat Diagn. 2013 Feb;33(2):173-8. doi: 10.1002/pd.4035. Epub 2012 Dec 20.

PMID:
23280558
10.

Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma.

Lo YM, Hjelm NM, Fidler C, Sargent IL, Murphy MF, Chamberlain PF, Poon PM, Redman CW, Wainscoat JS.

N Engl J Med. 1998 Dec 10;339(24):1734-8.

11.

Development and validation of multiplex real-time PCR assay for noninvasive prenatal assessment of fetal RhD status and fetal sex in maternal plasma.

Ordoñez E, Rueda L, Cañadas MP, Fuster C, Cirigliano V.

Fetal Diagn Ther. 2013;34(1):13-8. doi: 10.1159/000346809. Epub 2013 Mar 14.

PMID:
23548569
12.

Fetal RHD genotyping in maternal plasma at 11-13 weeks of gestation.

Akolekar R, Finning K, Kuppusamy R, Daniels G, Nicolaides KH.

Fetal Diagn Ther. 2011;29(4):301-6. doi: 10.1159/000322959. Epub 2011 Jan 8.

PMID:
21212654
13.

Fetal RhD genotyping by real time quantitative PCR in maternal plasma of RhD-negative pregnant women from the Sahel of Tunisia.

Moussa H, Tsochandaridis M, Jemni-Yacoub S, Hmida S, Khairi H, Gabert J, Levy-Mozziconacci A.

Ann Biol Clin (Paris). 2012 Nov-Dec;70(6):683-8. doi: 10.1684/abc.2012.0769.

14.

[Prenatal determination of fetal RHD in maternal plasma: two-years experience of routine clinical use].

Minon JM, Schaaps JP, Retz MC, Dricot JF, Foidart JM, Senterre JM.

J Gynecol Obstet Biol Reprod (Paris). 2005 Sep;34(5):448-53. French.

15.

Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study.

Benachi A, Delahaye S, Leticee N, Jouannic JM, Ville Y, Costa JM.

Eur J Obstet Gynecol Reprod Biol. 2012 May;162(1):28-32. doi: 10.1016/j.ejogrb.2012.02.001. Epub 2012 Mar 3.

PMID:
22386678
16.

Use of free fetal DNA in prenatal noninvasive detection of fetal RhD status and fetal gender by molecular analysis of maternal plasma.

Sedrak M, Hashad D, Adel H, Azzam A, Elbeltagy N.

Genet Test Mol Biomarkers. 2011 Sep;15(9):627-31. doi: 10.1089/gtmb.2010.0263. Epub 2011 Apr 13.

PMID:
21488716
17.

RHD genotyping from maternal plasma: guidelines and technical challenges.

Avent ND.

Methods Mol Biol. 2008;444:185-201. doi: 10.1007/978-1-59745-066-9_14. Review.

PMID:
18425481
18.

Noninvasive fetal RHD genotyping from maternal plasma in an admixed Brazilian population.

Schmidt LC, Cabral AC, Faria MA, Monken F, Tarazona-Santos E, Martins ML.

Genet Mol Res. 2014 Feb 7;13(1):799-805. doi: 10.4238/2014.February.7.1.

19.

Noninvasive fetal RHD genotyping from maternal plasma. Use of a new developed Free DNA Fetal Kit RhD.

Rouillac-Le Sciellour C, Sérazin V, Brossard Y, Oudin O, Le Van Kim C, Colin Y, Guidicelli Y, Menu M, Cartron JP.

Transfus Clin Biol. 2007 Dec;14(6):572-7. doi: 10.1016/j.tracli.2008.01.003. Epub 2008 Mar 28.

PMID:
18375165
20.

Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.

Tiblad E, Taune Wikman A, Ajne G, Blanck A, Jansson Y, Karlsson A, Nordlander E, Holländer BS, Westgren M.

PLoS One. 2013 Aug 6;8(8):e70984. doi: 10.1371/journal.pone.0070984. Print 2013.

Supplemental Content

Support Center